Literature DB >> 32158103

Dissecting Primary Erythrocytosis Among Polycythemia Patients Referred to an Indian Armed Forces Hospital.

Harshit Khurana1, Praveen Lakshman1, Kishore Kumar1, Arihant Jain2.   

Abstract

Referrals for evaluation of polycythemia cases have increased since the hemoglobin (Hb) thresholds for diagnosis of Polycythemia Vera (PV) have been lowered by WHO. The current study enrolled patients of age > 18 years from the Indian Armed Forces or their family members with polycythemia from November 2016 to October 2018. After exclusion of secondary causes, 49 patients were diagnosed as Primary Erythrocytosis (PE). The patients were classified into two groups: PV and Idiopathic Erythrocytosis (IE) and a systematic comparison of clinical and laboratory features of the two groups was done. The prevalence of PV in PE was 20.4% (10 of 49) while the rest 39 (79.6%) had IE. Seven PV patients had JAK2 V617F mutation, one had JAK2 Exon12 mutation, and two were JAK2 negative PV. Nine of 10 (90%) PV patients had Hb > 18.5 g/dl, while only 21 of 39 (53.8%) IE patients had Hb > 18.5 g/dl (p = 0.06). None of the JAK2 mutated patients had Hb < 18.5 g/dl. We conclude that PV is more prevalent in patients of PE with Hb > 18.5 g/dl. Most patients with Hb between 16.5-18.5 g/dl would still be classified as IE. We advocate the need for further studies evaluating the utility of investigating all patients of PE with the revised WHO Hb threshold as well as studies on genetic profile of IE patients from India. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Erythrocytosis; Erythropoietin; JAK2 mutation; Polycythemia

Year:  2019        PMID: 32158103      PMCID: PMC7042446          DOI: 10.1007/s12288-019-01155-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

1.  Genetic basis of unexplained erythrocytosis in Indian patients.

Authors:  Nabhajit Mallik; Prashant Sharma; Jasbir Kaur Hira; Sanjeev Chhabra; Sreejesh Sreedharanunni; Narender Kumar; Shano Naseem; Man Updesh Singh Sachdeva; Jasmina Ahluwalia; Pankaj Malhotra; Neelam Varma; Subhash Varma; Reena Das
Journal:  Eur J Haematol       Date:  2019-06-13       Impact factor: 2.997

2.  Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

Authors:  Mary F McMullin; D Bareford; P Campbell; A R Green; Claire Harrison; Beverley Hunt; D Oscier; M I Polkey; J T Reilly; E Rosenthal; Kate Ryan; T C Pearson; Bridget Wilkins
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

3.  Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.

Authors:  Ing Soo Tiong; Debora A Casolari; Sarah Moore; Tran Nguyen; Merel J M Van Velzen; Daniela Zantomio; Hamish S Scott; Richard J D'Andrea; Christopher N Hahn; David M Ross
Journal:  Br J Haematol       Date:  2016-05-02       Impact factor: 6.998

Review 4.  Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.

Authors:  Margherita Maffioli; Barbara Mora; Francesco Passamonti
Journal:  Clin Adv Hematol Oncol       Date:  2017-09

5.  Facing erythrocytosis: Results of an international physician survey.

Authors:  Elisa Rumi; Mary F McMullin; Claire Harrison; Martin H Ellis; Merav Barzilai; Nadav Sarid; Ruben Mesa; Chiara Paoli; Anna Angona; Emanuela Sant'Antonio; Virginia V Ferretti; Chiara Cavalloni; Ilaria C Casetti; Chiara Trotti; Tiziano Barbui
Journal:  Am J Hematol       Date:  2019-06-10       Impact factor: 10.047

6.  Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.

Authors:  Sudha Sazawal; Jyoti Bajaj; Sunita Chikkara; Sonal Jain; Rahul Bhargava; Manoranjan Mahapatra; Renu Saxena
Journal:  Indian J Med Res       Date:  2010-10       Impact factor: 2.375

Review 7.  Idiopathic erythrocytosis: a disappearing entity.

Authors:  Mary Frances McMullin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Thrombotic complications of polycythemia vera.

Authors:  S Varma; Aman Sharma; Pankaj Malhotra; S Kumari; S Jain; N Varma
Journal:  Hematology       Date:  2008-12       Impact factor: 2.269

9.  Polycythemia vera and idiopathic erythrocytosis: comparison of clinical and laboratory parameters.

Authors:  M Usman; F Bilwani; G N Kakepoto; S N Adil; R Sajid; M Khurshid
Journal:  J Pak Med Assoc       Date:  2004-05       Impact factor: 0.781

Review 10.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.